Shareholder Class Action Filed Against Corcept Therapeutics

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: 14 hours ago

0mins

CORT-1.32%

Should l Buy CORT?

Source: Globenewswire

Lawsuit Background: A shareholder class action lawsuit has been filed against Corcept Therapeutics, alleging that the company issued false and misleading statements regarding clinical trials and failed to disclose adverse facts related to its New Drug Application, potentially leading to investor losses.
Investor Impact: Investors who purchased Corcept shares between October 31, 2024, and December 30, 2025, and experienced significant losses are encouraged to consult legal counsel to understand their rights, which could affect the company's stock price and investor confidence.
Legal Representation: Holzer & Holzer, LLC, a law firm focused on shareholder rights and rated top by ISS from 2021 to 2025, is dedicated to vigorously representing shareholders, which may impact the company's reputation and future legal standing.
Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by April 21, 2026, or risk losing the opportunity to participate in the lawsuit, which could further affect the company's legal liabilities and financial health.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on CORT

Wall Street analysts forecast CORT stock price to rise

6 Analyst Rating

4 Buy

1 Hold

1 Sell

Moderate Buy

Current: 33.990

Low

50.00

Averages

91.00

High

121.00

Current: 33.990

Low

50.00

Averages

91.00

High

121.00

H.C. Wainwright

Swayampakula Ramakanth

Buy

downgrade

$67 -> $60

2026-02-25

Reason

H.C. Wainwright

Swayampakula Ramakanth

Price Target

$67 -> $60

AI Analysis

2026-02-25

downgrade

Buy

Reason

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on Corcept Therapeutics to $60 from $67 and keeps a Buy rating on the shares. Given typical seasonality and Corcept's pharmacy transition at the start of 2026, the firm expects a 19% sequential decline in the company's Q1 sales.

H.C. Wainwright

Buy

downgrade

$105 -> $67

2026-02-20

Reason

H.C. Wainwright

Price Target

$105 -> $67

2026-02-20

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Corcept Therapeutics (CORT) to $67 from $105 and keeps a Buy rating on the shares. The U.S. Court of Appeals for the Federal Circuit affirmed the District Court's ruling that Teva's (TEVA) generic Korlym does not infringe Corcept's patents, the analyst tells investors in a research note. The firm believes the decision "eliminates the bull-case scenario" for Corcept of halting generic erosion from the authorized generic, while confirming that Teva's generic can participate in the Cushing's syndrome market.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CORT

Unlock Now

About CORT

Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Corcept Therapeutics Faces Securities Class Action Lawsuit

10 hours agoGlobenewswire

Lawsuit Deadline: Investors must file lead plaintiff applications for the Corcept securities class action by April 21, 2026, concerning trades made between October 31, 2024, and December 30, 2025, highlighting investor concerns over potential losses.
Disclosure Failures: Corcept and its executives are accused of failing to disclose material information during the class period, violating federal securities laws, which severely undermined investor confidence in the company's new drug application.
Stock Price Plunge: Following the December 31, 2025 disclosure of the FDA's Complete Response Letter regarding its new drug application, Corcept's stock price plummeted by 50.4%, from $70.20 to $34.80, indicating a pessimistic outlook from the market on the company's future prospects.
Legal Consultation Opportunity: Investors can contact Kahn Swick & Foti to understand their legal rights and how to participate in the lawsuit, reflecting a strong demand among investors for recovering economic losses.

Corcept Lawsuit Reminder for Investors

11 hours agoPRnewswire

Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation among affected investors.
Case Background: The lawsuit alleges that Corcept made false statements regarding the clinical trials supporting the NDA for relacorilant, claiming that the evidence was “powerful support,” while the FDA had raised concerns about its adequacy, resulting in significant investor losses when the truth emerged.
Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.

Navan and Corcept Face Class Action Lawsuits

13 hours agoGlobenewswire

Navan IPO Issues: Navan conducted its IPO on October 30, 2025, selling approximately 36.9 million shares at $25 each, but due to undisclosed increases in sales and marketing expenses, its stock plummeted to $9.01 by the time the lawsuit commenced, representing a decline of over 60%, resulting in significant investor losses.
Lawsuit Deadlines: Navan shareholders must petition to serve as lead plaintiff by April 24, 2026, reflecting investor concerns over the company's transparency and financial health, which could impact future fundraising capabilities.
Corcept Approval Risks: Corcept's relacorilant faced a Complete Response Letter from the FDA on December 31, 2025, requiring additional evidence of effectiveness, causing its stock price to drop from $70.20 to $34.80, a 50.4% decline, highlighting significant uncertainties in the company's drug development.
FDA Communication Missteps: During the class period, Corcept claimed smooth communication with the FDA and confidence in its NDA submission, but the FDA's concerns about clinical evidence raised the risk of non-approval, exacerbating investor confidence issues.